Module

Therapy of Chronic Hepatitis B: What to Choose, When to Change, and When to Stop

Source: Hepatitis Annual Update 2008

Therapy of Chronic Hepatitis B: What to Choose, When to Change, and When to Stop

Co-Chair: Norah Terrault, MD, MPH

Faculty:
Ira M. Jacobson, MD

CME CREDIT INFORMATION

Release Date: 06/25/08

Expiration Date: 06/24/09

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.4 contact hours (0.14 CEUs)

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the available treatment options when initiating hepatitis B virus therapy
Recount the factors involved in determining when to continue vs change current therapy
List the endpoints of therapy used to determine when treatment should be discontinued
Discuss new treatment data and the advantages and disadvantages of current treatment options

Topics covered include:

What to Choose, When to Change and When to Stop
What to Choose: Interferon Alfa
What to Choose: Nucleos(t)ide Therapy
De Novo Monotherapy vs Combination Therapy
When to Change Therapy
Predicting Resistance and Proactive HBV On-Treatment Management
On-Treatment Roadmap Algorithm
On-Treatment Management: Switch vs Add?
When to Stop
Summary: Implications for Clinical Practice

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.